SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (732)8/11/2003 6:55:10 PM
From: keokalani'nui  Respond to of 2240
 
[SGEN's naked anti-CD30 Mab is in the clinic]

Seattle Genetics Reports Progress in its SGN-35 Program
Monday August 11, 9:04 am ET

BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 11, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today the publication of preclinical data on its SGN-35 product candidate, an antibody-drug conjugate (ADC), in the August 15, 2003 issue of Blood, the Journal of the American Society of Hematology.
The research illustrates that SGN-35 is highly efficacious at low doses and is capable of selectively targeting CD30-positive malignancies in models of Hodgkin's disease and certain types of non-Hodgkin's lymphoma.

"SGN-35 has yielded impressive preclinical data, demonstrating potent antitumor activity at doses as low as 0.5 milligram per kilogram," commented Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Based on these findings, we are developing SGN-35 for future clinical evaluation in patients with hematologic malignancies. In addition, we are investigating SGN-35 as a potential treatment for immunologic diseases."

SGN-35 (cAC10-vcMMAE) is an ADC composed of an anti-CD30 monoclonal antibody linked to a derivative of the highly potent, cell-killing drug Auristatin E using Seattle Genetics' proprietary, next-generation ADC technology. The synthetic drug-linker system is designed for stability while in the bloodstream, but allows for active drug release under conditions present within target tumor cells. This targeted approach to cancer therapy is intended to maximize the antitumor activity of SGN-35 while reducing the toxic side effects associated with traditional chemotherapy.

In addition to SGN-35, Seattle Genetics is actively evaluating other tumor-reactive monoclonal antibodies for use with its ADC technology. By arming monoclonal antibodies with potent drug payloads, Seattle Genetics can further exploit their potential as therapeutics. The company licenses its ADC technology to other companies developing targeted therapies for cancer and immunologic disease.



To: Icebrg who wrote (732)8/12/2003 6:24:31 PM
From: Icebrg  Read Replies (2) | Respond to of 2240
 

Quarterly Q2_03 Q1_03 Q4_02 Q3_02 Q2_02 Q1_02


Revenue
Contract rev. etc 2,3 4,0 6,0 14,6 8,1 10,8
Total revenue 2,3 4,0 6,0 14,6 8,1 10,8

Cost of Revenue -2,6 -3,9 -0,3 -1,5
Gross Profit 2,3 4,0 3,4 10,7 7,8 9,3

S,G & A -5,2 -5,7 -5,8 -5,8 -5,8 -5,4
R&D -23,8 -23,5 -26,1 -20,9 -18,4 -17,3
Depr. /Amort
Total Op. Expenses -28,9 -29,2 -31,9 -26,7 -24,2 -22,7

Operating Income -26,7 -25,2 -28,5 -16,0 -16,4 -13,4

Interest, net 0,8 -3,4 -37,1 -1,7 -1,5 -0,9

Other, net -3,2 -0,1 26,1 -36,3 -2,5 -1,6
Total Non-op -2,4 -3,5 -11,0 -38,0 -4,0 -2,5

NI before taxes -29,1 -28,7 -39,5 -54,0 -20,4 -15,9

NI after taxes -29,1 -28,7 -39,5 -54,0 -20,4 -15,9


12 months July - April- Dec 31 Dec 31 Dec 31 Dec 31 Dec 31
figures June March 2002 2001 2000 1999 1998

Revenue

Contract rev. etc 26,9 32,7 39,5 42,3 22,5 9,9 6,8
Total revenue 26,9 32,7 39,5 42,3 22,5 9,9 6,8

Cost of Revenue -6,5 -6,8 -8,3 -0,6 -1,2 -0,7 -1,2
Gross Profit 20,4 25,9 31,2 41,7 21,3 9,2 5,6

S,G & A -22,5 -23,1 -22,9 -19,3 -18,1 -8,0 -5,1
R&D -94,3 -88,9 -82,6 -38,6 -33,9 -19,9 -23,1

Other op. Expenses 0,0 0,0 0,0
Total Op. Expenses -116,7 -112,0 -105,5 -57,9 -52,0 -27,9 -28,2

Operating Income -96,4 -86,1 -74,3 -16,2 -30,7 -18,7 -22,6

Interest, net -41,4 -43,7 -41,2 14,2 20,8 1,2 0,4

Other, net -13,5 -12,8 -14,3
Total Non-op -54,9 -56,5 -55,5 14,2 20,8 1,2 0,4

NI before taxes -151,3 -142,6 -129,8 -2,0 -9,9 -17,5 -22,2

Prov. Taxes 0,0 0,0 -0,1 -0,6 13,1 0,5 -0,3
NI after taxes -151,3 -142,6 -129,9 -2,6 3,2 -17,0 -22,5



DD continues to spend money like I don't know what. Over the last 12m period the loss was 151 mUSD. Must be something of a record.

Erik